furancoumarins 对使用集成对接,分子动力学和 ONIOM 方法的环林依赖激酶 4 的抑制潜力
Srutishree Sarma1, Dikshita Dowerah1, Moumita Basumatary1
1CMML-Catalysis and Molecular Modelling Lab, Department of Chemical Sciences, Tezpur University, Sonitpur, Assam, India.
Journal of biomolecular structure & dynamics
|January 8, 2024
概括
这项研究选了50种富拉诺库马林,以检测其对循环林依赖激酶4 (CDK4) 的抑制. 诺托普特醇成为一种强大的CDK4抑制剂,为新的癌症药物设计提供了一个有前途的起点.
科学领域:
- 药用化学 医学化学
- 计算生物学 计算生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 循环依赖激酶4 (CDK4) 调节细胞周期G1检查点,其抑制是癌症治疗的目标.
- 目前的CDK4抗剂会对患者产生显著的副作用.
- 富拉诺库马林表现出抗癌性质,并被探索为CDK4向.
研究的目的:
- 为了研究50种 furancoumarin化合物的CDK4抑制潜力.
- 使用计算方法识别基于氨酸的新型CDK4抑制剂.
- 评估潜在抑制剂的药物相似性和药理动力学特性.
主要方法:
- 分子对接以预测结合亲和力.
- 药物相似性和药物动力学分析.
- 分子动力学模拟和ONIOM计算以评估稳定性和相互作用.
- 选50种子胺衍生物.
主要成果:
- 五种富拉诺库马林显示出有前途的对接分数和有利的药理动力学特征.
- 环氧贝加莫丁,二贝加莫丁和诺托醇在CDK4的ATP结合部位内表现出稳定的结合.
- 诺托醇表现出最强的结合能,并保持了关键的结相互作用,这是ONIOM计算证实的.
结论:
- 诺托醇通过全面的计算分析被确定为一种强大的CDK4抑制剂.
- 这项研究为开发基于notopterol的治疗方法提供了坚实的基础.
- 富拉诺库马林是癌症治疗中针对性CDK4抑制的一类有前途的化合物.
相关概念视频
02:34Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
02:39Positive Regulator Molecules
5.5K
Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
5.5K